Free Trial

Standard BioTools (LAB) Financials

Standard BioTools logo
$1.06 +0.03 (+2.43%)
As of 10:32 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Annual Income Statements for Standard BioTools

Annual Income Statements for Standard BioTools

This table shows Standard BioTools' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021
Net Income / (Loss) Attributable to Common Shareholders
-185 -75 -190 -59
Consolidated Net Income / (Loss)
-139 -75 -190 -59
Net Income / (Loss) Continuing Operations
-139 -75 -190 -59
Total Pre-Tax Income
-138 -74 -193 -64
Total Operating Income
-175 -77 -116 -67
Total Gross Profit
84 50 37 69
Total Revenue
174 106 98 131
Operating Revenue
174 106 98 131
Total Cost of Revenue
90 56 61 61
Operating Cost of Revenue
90 56 61 61
Total Operating Expenses
259 127 153 137
Selling, General & Admin Expense
157 88 102 99
Research & Development Expense
62 26 37 38
Restructuring Charge
40 14 14 -
Total Other Income / (Expense), net
37 2.40 -77 3.80
Interest Expense
3.32 4.57 4.33 3.82
Interest & Investment Income
20 5.57 2.23 0.00
Other Income / (Expense), net
20 1.39 -75 7.62
Income Tax Expense
0.57 0.45 -2.83 -4.42
Preferred Stock Dividends Declared
46 0.00 0.00 -
Basic Earnings per Share
($0.52) ($0.94) ($2.43) ($0.78)
Weighted Average Basic Shares Outstanding
353.25M 79.16M 78.31M 75.79M
Diluted Earnings per Share
($0.52) ($0.94) ($2.43) ($0.78)
Weighted Average Diluted Shares Outstanding
353.25M 79.16M 78.31M 75.79M
Weighted Average Basic & Diluted Shares Outstanding
378.99M 290.12M 79.06M 77.20M

Quarterly Income Statements for Standard BioTools

This table shows Standard BioTools' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 9/30/2024 6/30/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
-27 -46 -20 -21 -17 -17 -21 -29
Consolidated Net Income / (Loss)
-27 -46 -20 -21 -17 -17 -21 -29
Net Income / (Loss) Continuing Operations
-27 -46 -20 -21 -17 -17 -21 -29
Total Pre-Tax Income
-27 -46 -20 -21 -17 -17 -21 -30
Total Operating Income
-32 -51 -21 -21 -17 -17 -21 -29
Total Gross Profit
23 15 13 11 14 12 11 9.22
Total Revenue
45 37 28 25 28 25 27 26
Operating Revenue
45 37 28 25 28 25 27 26
Total Cost of Revenue
22 22 15 14 14 13 16 16
Operating Cost of Revenue
22 22 15 14 14 13 16 16
Total Operating Expenses
55 65 35 32 31 29 32 38
Selling, General & Admin Expense
34 38 21 22 23 21 15 26
Research & Development Expense
13 19 6.97 6.37 6.18 6.43 7.43 8.49
Restructuring Charge
7.42 8.53 6.48 3.66 2.27 1.15 - 3.42
Total Other Income / (Expense), net
4.90 4.86 1.45 0.23 0.71 0.01 0.34 -1.11
Interest & Investment Income
3.94 4.44 4.92 0.34 0.24 0.07 62 0.00
Other Income / (Expense), net
0.96 0.41 1.10 -0.12 0.47 -0.06 -61 -0.06
Income Tax Expense
0.12 0.06 -0.16 0.05 0.30 0.26 0.07 -0.71
Preferred Stock Dividends Declared
0.00 0.00 - 0.00 0.00 0.00 - -
Basic Earnings per Share
($0.07) ($0.12) ($0.24) ($0.27) ($0.22) ($0.21) ($0.25) ($0.37)
Weighted Average Basic Shares Outstanding
371.54M 372.33M 79.16M 79.15M 78.67M 79.08M 78.31M 78.90M
Diluted Earnings per Share
($0.07) ($0.12) ($0.24) ($0.27) ($0.22) ($0.21) ($0.25) ($0.37)
Weighted Average Diluted Shares Outstanding
371.54M 372.33M 79.16M 79.15M 78.67M 79.08M 78.31M 78.90M
Weighted Average Basic & Diluted Shares Outstanding
372.26M 371.15M 290.12M 79.40M 78.96M 78.38M 79.06M 79.30M

Annual Cash Flow Statements for Standard BioTools

This table details how cash moves in and out of Standard BioTools' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021
Net Change in Cash & Equivalents
116 -30 53 -40
Net Cash From Operating Activities
-143 -43 -89 -44
Net Cash From Continuing Operating Activities
-143 -43 -89 -44
Net Income / (Loss) Continuing Operations
-139 -75 -190 -59
Consolidated Net Income / (Loss)
-139 -75 -190 -59
Depreciation Expense
13 3.98 3.50 3.65
Amortization Expense
-3.09 9.94 11 13
Non-Cash Adjustments To Reconcile Net Income
8.31 15 101 18
Changes in Operating Assets and Liabilities, net
-22 2.73 -14 -19
Net Cash From Investing Activities
363 20 -88 -12
Net Cash From Continuing Investing Activities
363 20 -88 -12
Purchase of Property, Plant & Equipment
-8.36 -2.83 -3.83 -13
Acquisitions
-1.39 0.00 0.00 -
Purchase of Investments
-256 -95 -137 0.00
Sale and/or Maturity of Investments
349 118 53 0.00
Other Investing Activities, net
280 0.00 0.00 1.32
Net Cash From Financing Activities
-103 -6.81 231 16
Net Cash From Continuing Financing Activities
-103 -6.81 231 16
Repayment of Debt
-64 -2.08 -6.84 -0.50
Repurchase of Common Equity
-40 -5.41 -13 -0.08
Issuance of Debt
0.00 0.00 25 17
Issuance of Preferred Equity
0.00 0.00 225 0.00
Issuance of Common Equity
0.92 0.72 0.82 1.49
Other Financing Activities, net
0.69 -0.04 -0.11 -1.79
Effect of Exchange Rate Changes
-0.79 0.03 -0.40 -0.02
Cash Interest Paid
3.09 3.82 3.49 3.15
Cash Income Taxes Paid
0.61 0.80 0.31 2.09

Quarterly Cash Flow Statements for Standard BioTools

This table details how cash moves in and out of Standard BioTools' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
-43 -59 -28 -63 29 32 21 -14
Net Cash From Operating Activities
-14 -28 -14 -11 -9.33 -8.49 -19 -25
Net Cash From Continuing Operating Activities
-14 -28 -14 -11 -9.33 -8.49 -19 -25
Net Income / (Loss) Continuing Operations
-34 -27 -20 -21 -17 -17 -21 -29
Consolidated Net Income / (Loss)
-34 -27 -20 -21 -17 -17 -21 -29
Depreciation Expense
3.14 3.15 1.11 1.19 0.83 0.86 0.82 0.80
Amortization Expense
-0.32 -1.05 1.86 2.63 2.81 2.64 1.50 3.01
Non-Cash Adjustments To Reconcile Net Income
3.40 10 1.23 6.60 3.36 3.54 2.76 7.14
Changes in Operating Assets and Liabilities, net
14 -13 1.52 -0.83 0.71 1.32 -3.42 -6.13
Net Cash From Investing Activities
26 -31 -13 -50 40 43 40 11
Net Cash From Continuing Investing Activities
26 -31 -13 -50 40 43 40 11
Purchase of Property, Plant & Equipment
-3.38 -2.26 -0.08 -0.91 -0.84 -1.01 -0.76 -1.26
Purchase of Investments
-30 -79 -39 -49 - -6.84 - -
Sale and/or Maturity of Investments
60 50 26 - 41 51 41 12
Net Cash From Financing Activities
-55 -0.00 -1.00 -1.16 -2.08 -2.56 -0.27 -0.01
Net Cash From Continuing Financing Activities
-55 -0.00 -1.00 -1.16 -2.08 -2.56 -0.27 -0.01
Repayment of Debt
-55 - -1.25 -0.83 - 0.00 - -
Issuance of Common Equity
0.49 - 0.40 - - - 0.32 -
Other Financing Activities, net
-0.01 -0.00 0.02 0.07 -0.04 -0.09 -0.03 -0.01
Effect of Exchange Rate Changes
-0.27 -0.41 0.23 -0.15 -0.07 0.02 0.32 -0.28
Cash Interest Paid
1.44 0.00 1.65 0.25 1.69 0.23 1.65 0.17
Cash Income Taxes Paid
0.20 0.06 0.17 0.12 0.21 0.31 0.06 -0.39

Annual Balance Sheets for Standard BioTools

This table presents Standard BioTools' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021
Total Assets
612 323 390 275
Total Current Assets
376 158 209 72
Cash & Equivalents
167 52 81 28
Short-Term Investments
126 63 84 0.00
Accounts Receivable
34 20 17 18
Inventories, net
41 21 21 21
Prepaid Expenses
8.66 3.13 4.28 4.47
Plant, Property, & Equipment, net
43 24 26 28
Total Noncurrent Assets
194 141 156 175
Goodwill
111 106 106 106
Intangible Assets
29 1.40 13 28
Other Noncurrent Operating Assets
54 33 37 41
Total Liabilities & Shareholders' Equity
612 323 390 275
Total Liabilities
141 160 161 181
Total Current Liabilities
66 109 43 50
Short-Term Debt
0.00 60 2.08 6.84
Accounts Payable
12 9.24 7.91 11
Accrued Expenses
31 21 6.18 8.67
Current Deferred Revenue
17 15 14 15
Other Current Liabilities
6.23 4.32 3.68 3.05
Total Noncurrent Liabilities
75 51 117 131
Long-Term Debt
0.30 3.98 63 64
Noncurrent Deferred Revenue
33 3.52 3.82 5.97
Noncurrent Deferred & Payable Income Tax Liabilities
1.08 0.84 1.06 4.33
Other Noncurrent Operating Liabilities
41 42 49 57
Commitments & Contingencies
0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
0.00 311 311 0.00
Total Equity & Noncontrolling Interests
472 -148 -81 95
Total Preferred & Common Equity
472 -148 -81 95
Preferred Stock
0.00 0.00 0.00 0.00
Total Common Equity
472 -148 -81 95
Common Stock
1,703 861 847 832
Retained Earnings
-1,186 -1,001 -926 -736
Treasury Stock
-46 -5.98 -0.56 0.00
Accumulated Other Comprehensive Income / (Loss)
1.23 -2.22 -1.90 -0.91

Quarterly Balance Sheets for Standard BioTools

This table presents Standard BioTools' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
682 709 339 356 372 415
Total Current Assets
454 480 171 183 195 229
Cash & Equivalents
211 270 80 142 114 60
Short-Term Investments
156 125 49 0.00 41 125
Accounts Receivable
35 32 17 15 15 17
Inventories, net
43 43 22 22 23 22
Prepaid Expenses
9.32 10 3.40 3.57 3.37 4.61
Plant, Property, & Equipment, net
42 43 25 25 25 27
Total Noncurrent Assets
186 186 144 148 152 159
Goodwill
106 106 106 106 106 106
Intangible Assets
23 24 4.20 7.00 9.80 15
Other Noncurrent Operating Assets
56 56 34 35 36 38
Total Liabilities & Shareholders' Equity
682 709 339 356 372 415
Total Liabilities
192 198 160 158 158 166
Total Current Liabilities
121 124 52 47 44 46
Short-Term Debt
55 55 5.00 4.58 3.33 0.83
Accounts Payable
11 13 7.33 6.09 6.11 9.31
Accrued Expenses
32 32 10 7.18 6.88 6.91
Current Deferred Revenue
17 19 15 15 15 15
Other Current Liabilities
6.12 5.85 3.98 3.91 3.76 3.52
Total Noncurrent Liabilities
72 75 108 111 114 120
Long-Term Debt
0.30 0.30 60 61 62 64
Noncurrent Deferred Revenue
33 33 3.47 3.79 3.83 4.43
Noncurrent Deferred & Payable Income Tax Liabilities
0.84 0.84 1.02 1.05 1.05 0.62
Other Noncurrent Operating Liabilities
38 40 44 46 47 51
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
0.00 0.00 311 311 311 311
Total Equity & Noncontrolling Interests
489 510 -132 -113 -97 -63
Total Preferred & Common Equity
489 510 -132 -113 -97 -63
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
489 510 -132 -113 -97 -63
Common Stock
1,689 1,683 857 854 850 845
Retained Earnings
-1,152 -1,125 -981 -960 -943 -905
Treasury Stock
-46 -46 -5.80 -5.40 -3.03 -
Accumulated Other Comprehensive Income / (Loss)
-1.41 -1.50 -1.95 -1.55 -1.33 -2.61

Annual Metrics And Ratios for Standard BioTools

This table displays calculated financial ratios and metrics derived from Standard BioTools' official financial filings.

Metric 2024 2023 2022 2021
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021
Growth Metrics
- - - -
Revenue Growth
64.03% 8.57% -24.99% -5.47%
EBITDA Growth
-137.83% 65.27% -304.36% -36.20%
EBIT Growth
-106.35% 60.59% -218.90% -18.42%
NOPAT Growth
-128.77% 34.08% -72.26% -32.18%
Net Income Growth
-86.03% 60.73% -220.91% -11.73%
EPS Growth
44.68% 61.32% -211.54% -5.41%
Operating Cash Flow Growth
-231.40% 51.56% -102.83% -185.79%
Free Cash Flow Firm Growth
-419.87% 49.97% -22.44% -410.55%
Invested Capital Growth
60.21% -13.25% -6.05% 9.97%
Revenue Q/Q Growth
0.00% 1.11% -10.30% -4.63%
EBITDA Q/Q Growth
0.00% -2.61% -73.03% 13.42%
EBIT Q/Q Growth
0.00% -0.94% -61.57% 10.44%
NOPAT Q/Q Growth
0.00% -0.36% -9.26% 7.72%
Net Income Q/Q Growth
0.00% 1.41% -6.39% 12.67%
EPS Q/Q Growth
0.00% 1.05% -5.65% 14.29%
Operating Cash Flow Q/Q Growth
0.00% 10.58% -15.78% -8.01%
Free Cash Flow Firm Q/Q Growth
0.00% 10.09% -6.74% -15.85%
Invested Capital Q/Q Growth
0.00% -3.00% 0.65% 2.33%
Profitability Metrics
- - - -
Gross Margin
48.31% 47.44% 37.83% 53.13%
EBITDA Margin
-83.57% -57.64% -180.17% -33.42%
Operating Margin
-100.46% -72.03% -118.64% -51.66%
EBIT Margin
-88.97% -70.73% -194.82% -45.82%
Profit (Net Income) Margin
-79.62% -70.21% -194.08% -45.36%
Tax Burden Percent
100.41% 100.61% 98.53% 93.05%
Interest Burden Percent
89.12% 98.66% 101.10% 106.39%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-84.32% -44.55% -61.14% -36.05%
ROIC Less NNEP Spread (ROIC-NNEP)
-74.88% -16.92% 311.97% -120.97%
Return on Net Nonoperating Assets (RNNOA)
40.57% 6.56% -56.07% -14.65%
Return on Equity (ROE)
-43.75% -37.99% -117.21% -50.71%
Cash Return on Invested Capital (CROIC)
-130.59% -30.36% -54.90% -45.55%
Operating Return on Assets (OROA)
-33.18% -21.09% -57.35% -19.95%
Return on Assets (ROA)
-29.70% -20.93% -57.13% -19.75%
Return on Common Equity (ROCE)
-22.30% 22.19% -4.74% -50.71%
Return on Equity Simple (ROE_SIMPLE)
-29.44% 50.43% 233.34% -62.62%
Net Operating Profit after Tax (NOPAT)
-123 -54 -81 -47
NOPAT Margin
-70.32% -50.42% -83.05% -36.16%
Net Nonoperating Expense Percent (NNEP)
-9.43% -27.63% -373.11% 84.92%
Return On Investment Capital (ROIC_SIMPLE)
-25.99% 63.43% 490.76% -
Cost of Revenue to Revenue
51.69% 52.56% 62.17% 46.87%
SG&A Expenses to Revenue
89.78% 82.32% 104.43% 75.73%
R&D to Revenue
35.78% 24.40% 38.17% 29.06%
Operating Expenses to Revenue
148.77% 119.48% 156.47% 104.79%
Earnings before Interest and Taxes (EBIT)
-155 -75 -191 -60
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-146 -61 -176 -44
Valuation Ratios
- - - -
Price to Book Value (P/BV)
1.38 0.00 0.00 3.17
Price to Tangible Book Value (P/TBV)
1.97 0.00 0.00 0.00
Price to Revenue (P/Rev)
3.73 1.65 0.95 2.30
Price to Earnings (P/E)
0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
2.00 3.89 2.35 2.50
Enterprise Value to Revenue (EV/Rev)
2.06 4.09 3.09 2.62
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00
Leverage & Solvency
- - - -
Debt to Equity
0.00 0.39 0.28 0.75
Long-Term Debt to Equity
0.00 0.02 0.27 0.68
Financial Leverage
-0.54 -0.39 -0.18 0.12
Leverage Ratio
1.47 1.82 2.05 2.57
Compound Leverage Factor
1.31 1.79 2.07 2.73
Debt to Total Capital
0.06% 28.01% 22.02% 42.89%
Short-Term Debt to Total Capital
0.00% 26.26% 0.71% 4.13%
Long-Term Debt to Total Capital
0.06% 1.76% 21.31% 38.76%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 137.29% 105.62% 0.00%
Common Equity to Total Capital
99.94% -65.30% -27.65% 57.11%
Debt to EBITDA
0.00 -1.04 -0.37 -1.63
Net Debt to EBITDA
2.01 0.84 0.57 -0.98
Long-Term Debt to EBITDA
0.00 -0.07 -0.36 -1.47
Debt to NOPAT
0.00 -1.18 -0.80 -1.50
Net Debt to NOPAT
2.39 0.96 1.24 -0.90
Long-Term Debt to NOPAT
0.00 -0.07 -0.77 -1.36
Altman Z-Score
0.12 -3.94 -3.83 -2.89
Noncontrolling Interest Sharing Ratio
49.02% 158.40% 95.95% 0.00%
Liquidity Ratios
- - - -
Current Ratio
5.70 1.45 4.81 1.45
Quick Ratio
4.95 1.23 4.21 0.94
Cash Flow Metrics
- - - -
Free Cash Flow to Firm (FCFF)
-190 -37 -73 -60
Operating Cash Flow to CapEx
-1,716.98% -1,529.04% -2,336.47% -332.18%
Free Cash Flow to Firm to Interest Expense
-57.30 -8.00 -16.87 -15.61
Operating Cash Flow to Interest Expense
-43.26 -9.48 -20.64 -11.53
Operating Cash Flow Less CapEx to Interest Expense
-45.78 -10.10 -21.52 -14.99
Efficiency Ratios
- - - -
Asset Turnover
0.37 0.30 0.29 0.44
Accounts Receivable Turnover
6.55 5.76 5.50 5.97
Inventory Turnover
2.94 2.66 2.88 3.02
Fixed Asset Turnover
5.23 4.27 3.65 5.73
Accounts Payable Turnover
8.38 6.52 6.58 6.18
Days Sales Outstanding (DSO)
55.73 63.40 66.33 61.14
Days Inventory Outstanding (DIO)
124.01 137.16 126.76 120.80
Days Payable Outstanding (DPO)
43.55 56.00 55.49 59.10
Cash Conversion Cycle (CCC)
136.19 144.56 137.60 122.83
Capital & Investment Metrics
- - - -
Invested Capital
179 112 129 137
Invested Capital Turnover
1.20 0.88 0.74 1.00
Increase / (Decrease) in Invested Capital
67 -17 -8.30 12
Enterprise Value (EV)
359 435 303 342
Market Capitalization
651 175 93 300
Book Value per Share
$1.27 ($1.86) ($1.03) $1.24
Tangible Book Value per Share
$0.89 ($3.22) ($2.53) ($0.52)
Total Capital
472 227 295 166
Total Debt
0.30 64 65 71
Total Long-Term Debt
0.30 3.98 63 64
Net Debt
-293 -51 -101 43
Capital Expenditures (CapEx)
8.36 2.83 3.83 13
Debt-free, Cash-free Net Working Capital (DFCFNWC)
17 -6.48 1.67 0.89
Debt-free Net Working Capital (DFNWC)
310 108 167 29
Net Working Capital (NWC)
310 49 165 22
Net Nonoperating Expense (NNE)
16 21 109 12
Net Nonoperating Obligations (NNO)
-293 -51 -101 43
Total Depreciation and Amortization (D&A)
9.43 14 14 16
Debt-free, Cash-free Net Working Capital to Revenue
9.81% -6.09% 1.71% 0.68%
Debt-free Net Working Capital to Revenue
177.71% 101.95% 170.96% 22.47%
Net Working Capital to Revenue
177.71% 45.97% 168.84% 17.23%
Earnings Adjustments
- - - -
Adjusted Basic Earnings per Share
($0.52) ($0.94) ($2.43) ($0.78)
Adjusted Weighted Average Basic Shares Outstanding
353.25M 79.16M 78.31M 75.79M
Adjusted Diluted Earnings per Share
($0.52) ($0.94) ($2.43) ($0.78)
Adjusted Weighted Average Diluted Shares Outstanding
353.25M 79.16M 78.31M 75.79M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
378.99M 290.12M 79.06M 77.20M
Normalized Net Operating Profit after Tax (NOPAT)
-94 -44 -72 -47
Normalized NOPAT Margin
-54.08% -41.50% -73.34% -36.16%
Pre Tax Income Margin
-79.29% -69.78% -196.97% -48.75%
Debt Service Ratios
- - - -
EBIT to Interest Expense
-46.80 -16.47 -44.06 -15.65
NOPAT to Interest Expense
-36.99 -11.74 -18.78 -12.35
EBIT Less CapEx to Interest Expense
-49.32 -17.09 -44.94 -19.12
NOPAT Less CapEx to Interest Expense
-39.51 -12.36 -19.66 -15.82
Payout Ratios
- - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-29.15% -7.25% -6.90% -0.13%

Quarterly Metrics And Ratios for Standard BioTools

This table displays calculated financial ratios and metrics derived from Standard BioTools' official financial filings.

Metric Q3 2024 Q2 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 9/30/2024 6/30/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - -
Revenue Growth
77.27% 34.48% 4.32% -1.09% 47.34% -5.23% -29.38% -10.03%
EBITDA Growth
-64.05% -275.53% 78.23% 30.90% 64.66% 61.15% -1,463.05% -147.65%
EBIT Growth
-44.51% -195.04% 75.23% 26.82% 59.37% 56.23% -792.95% -103.47%
NOPAT Growth
-49.81% -189.52% -1.30% 27.06% 54.75% 39.67% -87.51% -48.01%
Net Income Growth
-28.29% -168.30% 5.13% 28.64% 73.18% 77.92% -121.05% -112.57%
EPS Growth
74.07% 45.45% 4.00% 27.03% 73.17% 78.79% -108.33% -105.56%
Operating Cash Flow Growth
-144.21% 0.00% 26.69% 53.63% 68.89% 45.57% -173.94% -159.23%
Free Cash Flow Firm Growth
-4,079.08% -1,346.95% 132.46% 85.76% 72.74% -382.28% 68.11% -1.79%
Invested Capital Growth
54.60% 41.24% -13.25% -9.98% -4.98% 35.23% -6.05% -4.49%
Revenue Q/Q Growth
20.87% 0.00% 11.12% -8.31% 10.14% -7.04% 5.36% 36.58%
EBITDA Q/Q Growth
42.80% 0.00% 0.86% -30.94% -1.43% 16.55% -214.74% 33.03%
EBIT Q/Q Growth
38.61% 0.00% 4.70% -25.34% -1.99% 14.98% -181.51% 30.41%
NOPAT Q/Q Growth
37.22% 0.00% -1.01% -21.34% -5.16% 21.40% 27.27% 24.73%
Net Income Q/Q Growth
41.08% 0.00% 5.82% -23.22% -1.17% 19.20% 29.16% 53.69%
EPS Q/Q Growth
41.67% 0.00% 11.11% -22.73% -4.76% 16.00% 32.43% 54.88%
Operating Cash Flow Q/Q Growth
0.00% 0.00% -23.21% -22.33% -9.95% 55.76% 22.06% 17.93%
Free Cash Flow Firm Q/Q Growth
0.05% 0.00% 203.26% 65.39% 86.65% -580.25% 54.69% 33.78%
Invested Capital Q/Q Growth
4.45% 0.00% -3.00% -4.58% -3.07% -3.31% 0.65% 0.73%
Profitability Metrics
- - - - - - - -
Gross Margin
51.73% 40.07% 47.58% 43.97% 49.17% 48.89% 41.33% 35.95%
EBITDA Margin
-63.74% -134.68% -61.45% -68.87% -48.23% -52.37% -294.49% -98.58%
Operating Margin
-70.53% -135.79% -75.87% -83.46% -63.07% -66.06% -78.13% -113.18%
EBIT Margin
-68.40% -134.68% -71.97% -83.92% -61.39% -66.29% -303.07% -113.43%
Profit (Net Income) Margin
-59.90% -122.88% -70.16% -82.77% -61.59% -67.05% -77.14% -114.74%
Tax Burden Percent
100.44% 100.12% 99.19% 100.24% 101.80% 101.59% 100.34% 97.63%
Interest Burden Percent
87.19% 91.13% 98.28% 98.40% 98.56% 99.57% 25.37% 103.61%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% -46.92% -50.50% -37.55% -41.19% -40.27% -66.01%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% -40.61% -43.82% -33.24% 12.65% -19.45% -44.76%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 15.74% 18.91% 15.77% -1.04% 3.50% 11.03%
Return on Equity (ROE)
0.00% 0.00% -31.19% -31.60% -21.79% -42.23% -36.77% -54.98%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% -30.36% -33.41% -42.43% -97.95% -54.90% -52.21%
Operating Return on Assets (OROA)
0.00% 0.00% -21.46% -23.40% -16.25% -19.89% -89.21% -35.53%
Return on Assets (ROA)
0.00% 0.00% -20.92% -23.09% -16.30% -20.12% -22.71% -35.94%
Return on Common Equity (ROCE)
0.00% 0.00% 18.21% 14.36% 6.97% 13.42% -1.49% -5.78%
Return on Equity Simple (ROE_SIMPLE)
0.00% 0.00% 0.00% 57.49% 74.22% 134.48% 0.00% 284.77%
Net Operating Profit after Tax (NOPAT)
-22 -35 -15 -15 -12 -12 -15 -20
NOPAT Margin
-49.37% -95.05% -53.11% -58.42% -44.15% -46.24% -54.69% -79.23%
Net Nonoperating Expense Percent (NNEP)
-2.52% -4.97% -6.31% -6.69% -4.31% -53.84% -20.81% -21.25%
Cost of Revenue to Revenue
48.27% 59.93% 52.42% 56.03% 50.84% 51.11% 58.67% 64.05%
SG&A Expenses to Revenue
76.50% 101.26% 75.76% 87.88% 81.69% 84.78% 55.46% 102.71%
R&D to Revenue
29.26% 51.67% 24.71% 25.11% 22.35% 25.59% 27.48% 33.09%
Operating Expenses to Revenue
122.26% 175.86% 123.45% 127.43% 112.24% 114.95% 119.46% 149.13%
Earnings before Interest and Taxes (EBIT)
-31 -50 -20 -21 -17 -17 -82 -29
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-29 -50 -17 -17 -13 -13 -80 -25
Valuation Ratios
- - - - - - - -
Price to Book Value (P/BV)
1.46 1.29 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
1.99 1.73 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.00 0.00 1.65 2.18 1.43 1.60 0.95 0.79
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
2.27 1.87 3.89 4.13 3.19 3.02 2.35 2.17
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 4.09 4.53 3.66 3.89 3.09 2.54
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - -
Debt to Equity
0.11 0.11 0.39 0.36 0.33 0.30 0.28 0.26
Long-Term Debt to Equity
0.00 0.00 0.02 0.33 0.31 0.29 0.27 0.26
Financial Leverage
-0.56 -0.59 -0.39 -0.43 -0.47 -0.08 -0.18 -0.25
Leverage Ratio
1.53 1.50 1.82 1.76 1.69 2.72 2.05 2.00
Compound Leverage Factor
1.33 1.37 1.78 1.73 1.67 2.71 0.52 2.08
Debt to Total Capital
10.14% 9.74% 28.01% 26.46% 24.80% 23.31% 22.02% 20.66%
Short-Term Debt to Total Capital
10.08% 9.69% 26.26% 2.05% 1.74% 1.19% 0.71% 0.27%
Long-Term Debt to Total Capital
0.05% 0.05% 1.76% 24.41% 23.06% 22.11% 21.31% 20.40%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 137.29% 127.50% 118.30% 111.49% 105.62% 99.37%
Common Equity to Total Capital
89.86% 90.26% -65.30% -53.96% -43.09% -34.80% -27.65% -20.03%
Debt to EBITDA
0.00 0.00 -1.04 -1.08 -0.97 -0.71 -0.37 -0.63
Net Debt to EBITDA
0.00 0.00 0.84 1.08 1.14 0.97 0.57 1.18
Long-Term Debt to EBITDA
0.00 0.00 -0.07 -1.00 -0.90 -0.67 -0.36 -0.63
Debt to NOPAT
0.00 0.00 -1.18 -1.21 -1.11 -0.88 -0.80 -0.87
Net Debt to NOPAT
0.00 0.00 0.96 1.20 1.31 1.21 1.24 1.62
Long-Term Debt to NOPAT
0.00 0.00 -0.07 -1.12 -1.03 -0.84 -0.77 -0.86
Altman Z-Score
0.00 0.00 -3.37 -2.66 -2.60 -2.36 -2.91 -2.18
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 158.40% 145.43% 131.98% 131.77% 95.95% 89.48%
Liquidity Ratios
- - - - - - - -
Current Ratio
3.76 3.88 1.45 3.30 3.91 4.45 4.81 4.96
Quick Ratio
3.33 3.45 1.23 2.81 3.36 3.86 4.21 4.39
Cash Flow Metrics
- - - - - - - -
Free Cash Flow to Firm (FCFF)
-85 -85 2.10 -2.04 -5.89 -44 -6.48 -14
Operating Cash Flow to CapEx
-1,235.88% 0.00% -18,026.92% -1,260.99% -1,113.25% -840.10% -2,540.53% -1,947.07%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -5.45 -13.63
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -16.12 -23.46
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -16.75 -24.67
Efficiency Ratios
- - - - - - - -
Asset Turnover
0.00 0.00 0.30 0.28 0.26 0.30 0.29 0.31
Accounts Receivable Turnover
0.00 0.00 5.76 6.21 8.09 6.45 5.50 7.04
Inventory Turnover
0.00 0.00 2.66 2.60 2.64 2.60 2.88 2.72
Fixed Asset Turnover
0.00 0.00 4.27 4.11 4.07 3.66 3.65 3.94
Accounts Payable Turnover
0.00 0.00 6.52 6.85 7.84 6.39 6.58 6.28
Days Sales Outstanding (DSO)
0.00 0.00 63.40 58.74 45.09 56.56 66.33 51.86
Days Inventory Outstanding (DIO)
0.00 0.00 137.16 140.55 138.37 140.43 126.76 134.40
Days Payable Outstanding (DPO)
0.00 0.00 56.00 53.28 46.58 57.16 55.49 58.14
Cash Conversion Cycle (CCC)
0.00 0.00 144.56 146.01 136.88 139.82 137.60 128.12
Capital & Investment Metrics
- - - - - - - -
Invested Capital
178 171 112 115 121 125 129 128
Invested Capital Turnover
0.00 0.00 0.88 0.86 0.85 0.89 0.74 0.83
Increase / (Decrease) in Invested Capital
63 50 -17 -13 -6.33 32 -8.30 -6.02
Enterprise Value (EV)
405 319 435 476 385 376 303 277
Market Capitalization
716 659 175 229 151 154 93 87
Book Value per Share
$1.32 $1.37 ($1.86) ($1.67) ($1.45) ($1.23) ($1.03) ($0.80)
Tangible Book Value per Share
$0.97 $1.02 ($3.22) ($3.07) ($2.89) ($2.70) ($2.53) ($2.34)
Total Capital
545 565 227 244 263 279 295 313
Total Debt
55 55 64 65 65 65 65 65
Total Long-Term Debt
0.30 0.30 3.98 60 61 62 63 64
Net Debt
-311 -340 -51 -64 -77 -89 -101 -120
Capital Expenditures (CapEx)
2.26 0.00 0.08 0.91 0.84 1.01 0.76 1.26
Debt-free, Cash-free Net Working Capital (DFCFNWC)
22 16 -6.48 -4.91 -1.49 -0.06 1.67 -1.49
Debt-free Net Working Capital (DFNWC)
388 411 108 124 141 154 167 184
Net Working Capital (NWC)
333 356 49 119 136 151 165 183
Net Nonoperating Expense (NNE)
4.74 10 4.81 6.18 4.83 5.23 6.07 9.11
Net Nonoperating Obligations (NNO)
-311 -340 -51 -64 -77 -89 -101 -120
Total Depreciation and Amortization (D&A)
2.10 0.00 2.97 3.82 3.64 3.50 2.32 3.81
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% -6.09% -4.67% -1.41% -0.07% 1.71% -1.36%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 101.95% 117.84% 133.53% 159.97% 170.96% 168.22%
Net Working Capital to Revenue
0.00% 0.00% 45.97% 113.09% 129.19% 156.52% 168.84% 167.46%
Earnings Adjustments
- - - - - - - -
Adjusted Basic Earnings per Share
($0.07) ($0.12) ($0.24) ($0.27) ($0.22) ($0.21) ($0.25) ($0.37)
Adjusted Weighted Average Basic Shares Outstanding
371.54M 372.33M 79.16M 79.15M 78.67M 79.08M 78.31M 78.90M
Adjusted Diluted Earnings per Share
($0.07) ($0.12) ($0.24) ($0.27) ($0.22) ($0.21) ($0.25) ($0.37)
Adjusted Weighted Average Diluted Shares Outstanding
371.54M 372.33M 79.16M 79.15M 78.67M 79.08M 78.31M 78.90M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
372.26M 371.15M 290.12M 79.40M 78.96M 78.38M 79.06M 79.30M
Normalized Net Operating Profit after Tax (NOPAT)
-17 -29 -10 -12 -11 -11 -15 -18
Normalized NOPAT Margin
-37.82% -79.00% -37.02% -48.31% -38.41% -43.04% -54.69% -69.89%
Pre Tax Income Margin
-59.64% -122.73% -70.73% -82.58% -60.50% -66.01% -76.88% -117.52%
Debt Service Ratios
- - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -68.82 -27.73
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -12.42 -19.37
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -69.45 -28.94
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -13.05 -20.57
Payout Ratios
- - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% -7.25% -7.66% -6.42% -11.92% -6.90% -7.05%

Frequently Asked Questions About Standard BioTools' Financials

When does Standard BioTools's fiscal year end?

According to the most recent income statement we have on file, Standard BioTools' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Standard BioTools' net income changed over the last 3 years?

Standard BioTools' net income appears to be on an upward trend, with a most recent value of -$138.89 million in 2024, rising from -$59.24 million in 2021. The previous period was -$74.66 million in 2023. See Standard BioTools' forecast for analyst expectations on what’s next for the company.

What is Standard BioTools's operating income?
Standard BioTools's total operating income in 2024 was -$175.24 million, based on the following breakdown:
  • Total Gross Profit: $84.26 million
  • Total Operating Expenses: $259.50 million
How has Standard BioTools revenue changed over the last 3 years?

Over the last 3 years, Standard BioTools' total revenue changed from $130.58 million in 2021 to $174.43 million in 2024, a change of 33.6%.

How much debt does Standard BioTools have?

Standard BioTools' total liabilities were at $140.62 million at the end of 2024, a 12.0% decrease from 2023, and a 22.1% decrease since 2021.

How much cash does Standard BioTools have?

In the past 3 years, Standard BioTools' cash and equivalents has ranged from $28.45 million in 2021 to $166.73 million in 2024, and is currently $166.73 million as of their latest financial filing in 2024.

How has Standard BioTools' book value per share changed over the last 3 years?

Over the last 3 years, Standard BioTools' book value per share changed from 1.24 in 2021 to 1.27 in 2024, a change of 2.5%.



This page (NASDAQ:LAB) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners